Eruptive pseudoangiomatosis and SARS‐CoV‐2 (COVID‐19) infection

Caldarelli, Agostina Alonzo; Barba, Paula Johana; Hurtado, Mariana

doi:10.1111/ijd.15598

Cited by 11 publications

(20 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agirgol et al 5 described the appearance of diffuse cherry angioma-like lesions on the upper body of a middle-aged man, who had previously developed an erythematous, papulovesicular and later livedoidrash during mild COVID-19. Analogously, Caldarelli et al 6 described typical EP in a middle-aged woman with concurrent COVID-19 pneumonia. Unfortunately, both reports lacked histopathological confirmation.…”

mentioning

confidence: 74%

Eruptive pyogenic granulomas following coronavirus disease 2019

Maronese

Moltrasio

Marletta

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

mentioning

confidence: 74%

Eruptive pyogenic granulomas following coronavirus disease 2019

Maronese

Moltrasio

Marletta

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

“…In fact, EPA has been reported to develop following COVID‐19 infection as well. 7 The latency between infection and onset of EPA further supports the role of delayed hypersensitivity reaction. This suggests that the viral mRNA mounts an immunological response or causes cytokinemia.…”

mentioning

confidence: 85%

Development of delayed dermal hypersensitivity reaction following the second dose of COVID‐19 vaccine – A series of 37 cases

Mohta

Sharma²

2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

received the mRNA COVID-19 vaccine revealed that circulating anti-SARS-CoV-2 antibodies do not cross-react with pemphigus or pemphigoid autoantigens including desmoglein 1, desmoglein 3, envoplakin, BP180, BP230 and type VII collagen. 4 This argues against a link between SARS-CoV-2 vaccines and AIBDs with respect to disease-triggering antibody cross-reactivity.In conclusion, although further observational studies on that controversial topic are needed, current epidemiological and mechanistic data basically encourage COVID-19 vaccination in patients with AIBDs since benefits of vaccination far outweigh these reported uncommon, questionable, and otherwise manageable risks. This is of particular relevance in terms of patient counselling and physician endorsement, considering that SARS-CoV-2 vaccine hesitancy is prevalent across the AIBD population (approximately one third), with concern regarding immunobullous exacerbation representing a major factor contributing to hesitancy. 3

show abstract

“…Clinically, the lesions are asymptomatic bright red macules and papules with blanched perilesional halos, resolving on their own Cases of EP following COVID-19 have been sparsely reported. 2,3 Till date, only 6 cases of EP secondary to COVID-19 vaccine have been reported in literature. 4,5 The proposed hypothesis is upregulation of cellular and humoral immunity against the spike protein in the viral vaccine stimulating a paraviral response.…”

Section: Clinical Histopathological and Dermatoscopic Characterizatio...mentioning

confidence: 99%